Nykode Therapeutics ASA Net Assets
Nykode Therapeutics ASA net assets. Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has net assets worth Nkr80.39 Million NOK (≈ $8.46 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr86.11 Million ≈ $9.06 Million USD) and total liabilities (Nkr5.73 Million ≈ $602.86K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Nykode Therapeutics ASA (NYKD) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr80.39 Million |
| % of Total Assets | 93.35% |
| Annual Growth Rate | 16.48% |
| 5-Year Change | -52.83% |
| 10-Year Change | N/A |
| Growth Volatility | 247.96 |
Net Assets of Nykode Therapeutics ASA (2016–2025)
Net assets of Nykode Therapeutics ASA from 2016 to 2025. This chart illustrates how Nykode Therapeutics ASA's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Nykode Therapeutics ASA to measure how much of total assets are equity-financed.
Annual Net Assets for Nykode Therapeutics ASA (2016–2025)
The table below shows the annual net assets of Nykode Therapeutics ASA from 2016 to 2025. For live market cap and overall valuation, see NYKD market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr91.54 Million ≈ $9.63 Million |
-32.80% |
| 2024-12-31 | Nkr136.21 Million ≈ $14.33 Million |
-20.46% |
| 2023-12-31 | Nkr171.26 Million ≈ $18.02 Million |
+9.07% |
| 2022-12-31 | Nkr157.02 Million ≈ $16.52 Million |
-19.09% |
| 2021-12-31 | Nkr194.06 Million ≈ $20.42 Million |
+8.50% |
| 2020-12-31 | Nkr178.85 Million ≈ $18.82 Million |
-26.27% |
| 2019-12-31 | Nkr242.56 Million ≈ $25.52 Million |
+73.17% |
| 2018-12-31 | Nkr140.07 Million ≈ $14.74 Million |
-31.18% |
| 2017-12-31 | Nkr203.53 Million ≈ $21.42 Million |
+777.80% |
| 2016-12-31 | Nkr23.19 Million ≈ $2.44 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nykode Therapeutics ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 290566800.0% over the analyzed period, indicating profitable operations and earnings retention.
Nykode Therapeutics ASA Net Assets Breakdown (December 2025)
Nykode Therapeutics ASA net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Nkr367.00K | 0.40% |
| Other Components | Nkr93.70 Million | 102.36% |
| Total Equity | Nkr91.54 Million | 100.00% |
Nykode Therapeutics ASA Competitors by Market Cap
The table below lists competitors of Nykode Therapeutics ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Atlas Salt Inc
V:SALT
|
$123.19 Million |
|
Donpon Precision
TWO:3290
|
$123.21 Million |
|
Ellington Residential Mortgage
NYSE:EARN
|
$123.23 Million |
|
Wendell Industrial Co. Ltd
TWO:6761
|
$123.28 Million |
|
Adel Kalemcilik Ticaret ve Sanayi AS
IS:ADEL
|
$123.16 Million |
|
Airtel Africa Plc
LSE:AAF
|
$123.16 Million |
|
Pioneer Floating Rate Trust
NYSE:PHD
|
$123.13 Million |
|
OM Holdings Ltd
KLSE:5298
|
$123.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nykode Therapeutics ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 136,214,000 to 91,537,000, a change of -44,677,000 (-32.8%).
- Net loss of 12,240,000 reduced equity.
- Dividend payments of 32,279,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-12.24 Million | -13.37% |
| Dividends Paid | Nkr32.28 Million | -35.26% |
| Other Changes | Nkr-158.00K | -0.17% |
| Total Change | Nkr- | -32.80% |
Book Value vs Market Value Analysis
This analysis compares Nykode Therapeutics ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.67x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 7.20x to 10.67x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Nkr0.42 | Nkr2.99 | x |
| 2017-12-31 | Nkr0.84 | Nkr2.99 | x |
| 2018-12-31 | Nkr0.58 | Nkr2.99 | x |
| 2019-12-31 | Nkr0.83 | Nkr2.99 | x |
| 2020-12-31 | Nkr0.61 | Nkr2.99 | x |
| 2021-12-31 | Nkr0.73 | Nkr2.99 | x |
| 2022-12-31 | Nkr0.52 | Nkr2.99 | x |
| 2023-12-31 | Nkr0.57 | Nkr2.99 | x |
| 2024-12-31 | Nkr0.42 | Nkr2.99 | x |
| 2025-12-31 | Nkr0.28 | Nkr2.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nykode Therapeutics ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-13.37%) is below the historical average (-12.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -6.92% | -6674.84% | 0.00x | 1.08x | Nkr-3.92 Million |
| 2017 | -15.41% | -321.31% | 0.05x | 1.05x | Nkr-51.72 Million |
| 2018 | -45.54% | -529.75% | 0.08x | 1.09x | Nkr-77.80 Million |
| 2019 | -49.57% | -969.97% | 0.04x | 1.21x | Nkr-144.49 Million |
| 2020 | 83.74% | 69.66% | 0.93x | 1.29x | Nkr131.89 Million |
| 2021 | -4.85% | -27.72% | 0.13x | 1.37x | Nkr-28.82 Million |
| 2022 | -27.22% | -596.30% | 0.03x | 1.41x | Nkr-58.44 Million |
| 2023 | -20.53% | -272.47% | 0.06x | 1.22x | Nkr-52.28 Million |
| 2024 | -28.50% | -447.30% | 0.06x | 1.13x | Nkr-52.44 Million |
| 2025 | -13.37% | 0.00% | 0.00x | 1.09x | Nkr-21.39 Million |
Industry Comparison
This section compares Nykode Therapeutics ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $148,639,652
- Average return on equity (ROE) among peers: -1945.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nykode Therapeutics ASA (NYKD) | Nkr80.39 Million | -6.92% | 0.07x | $123.19 Million |
| Arcticzymes Technologies ASA (AZT) | $244.84 Million | 18.94% | 0.16x | $111.25 Million |
| Bergenbio ASA (BGBIO) | $337.28 Million | -56.85% | 0.12x | $7.75 Million |
| Circio Holding ASA (CRNA) | $2.57 Million | -16870.54% | 38.13x | $278.35 Million |
| Exact Therapeutics AS (EXTX) | $45.10 Million | -107.17% | 0.36x | $4.66 Million |
| Lytix Biopharma AS (LYTIX) | $189.62 Million | -25.34% | 0.07x | $63.93 Million |
| Oncoinvent ASA (ONCIN) | $127.48 Million | -149.36% | 0.37x | $29.50 Million |
| PCI Biotech Holding ASA (PCIB) | $189.24 Million | -38.17% | 0.11x | $274.95K |
| SoftOx Solutions AS (SOFTX) | $22.95 Million | -47.11% | 0.48x | $27.85 Million |
| Thor Medical ASA (TRMED) | $178.67 Million | -233.44% | 0.76x | $182.95 Million |
About Nykode Therapeutics ASA
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication… Read more